368 related articles for article (PubMed ID: 28499022)
1. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
Grossmann P; Narayan V; Chang K; Rahman R; Abrey L; Reardon DA; Schwartz LH; Wen PY; Alexander BM; Huang R; Aerts HJWL
Neuro Oncol; 2017 Nov; 19(12):1688-1697. PubMed ID: 28499022
[TBL] [Abstract][Full Text] [Related]
2. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
3. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
4. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
5. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
[TBL] [Abstract][Full Text] [Related]
6. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
[TBL] [Abstract][Full Text] [Related]
7. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
Kickingereder P; Götz M; Muschelli J; Wick A; Neuberger U; Shinohara RT; Sill M; Nowosielski M; Schlemmer HP; Radbruch A; Wick W; Bendszus M; Maier-Hein KH; Bonekamp D
Clin Cancer Res; 2016 Dec; 22(23):5765-5771. PubMed ID: 27803067
[TBL] [Abstract][Full Text] [Related]
8. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
[TBL] [Abstract][Full Text] [Related]
10. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI.
Lescher S; Jurcoane A; Veit A; Bähr O; Deichmann R; Hattingen E
Neuroradiology; 2015 Jan; 57(1):11-20. PubMed ID: 25287076
[TBL] [Abstract][Full Text] [Related]
11. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
[TBL] [Abstract][Full Text] [Related]
12. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
Chang K; Zhang B; Guo X; Zong M; Rahman R; Sanchez D; Winder N; Reardon DA; Zhao B; Wen PY; Huang RY
Neuro Oncol; 2016 Dec; 18(12):1680-1687. PubMed ID: 27257279
[TBL] [Abstract][Full Text] [Related]
13. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
[TBL] [Abstract][Full Text] [Related]
14. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
17. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
18. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
19. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
20. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
